Navigation Links
Vela Laboratories Receives the GMP Certificate for Its Analytical and Quality Control Laboratories
Date:4/7/2008

VIENNA, April 7 /PRNewswire/ -- Vela Laboratories announced today that it has received the GMP certificate for its analytical and quality control laboratories. "Good Manufacturing Practice" is a body of internationally accepted regulations set forth by EU and US drug agencies. GMP compliance ensures that pharmaceuticals , active ingredients and medical devices are pro­duced and quality-controlled according to state-of-the-art standards.

"GMP compliance is the gold standard in quality assurance in the life science industry. It is a major achievement for Vela Labs to have reached the GMP certification just 18 months since its formation," said Dr. Markus Fido, founder and CEO of Vela Laboratories. "Now that Vela Laboratories is GMP certified, its analytical services fully qualify to support clinical studies as well as regulatory submissions."

"GMP certification is an important milestone for our analytical services business. Now we will start to consistently expand our analytical methods portfolio that we are offering to the pharmaceutical and biotech industry," said Dr. Andreas Nechansky, founder of Vela Labo­ratories and Chief Operating Officer.

"Having achieved GMP compliance enables Vela to develop its therapeutic anti-cancer anti­bodies in the shortest time possible and with the highest quality," said Dr. Ralf Kircheis, founder of Vela Laboratories and Chief Scientific Officer.

About Vela Laboratories

Vela Laboratories (Vela pharmazeutische Entwicklung und Laboranalytik GmbH) provides a broad portfolio of analytical methods for the preclinical and clinical development including studies in support of regulatory submissions and product release for biopharmaceuticals.

Additionally, Vela Laboratories develops innovative immunotherapeutics for the treatment of cancer, including therapeutic antibodies and multi-epitope vaccines. Vela Laboratories' lead product, a humanized monoclonal antibody against a common tumor antigen, is in clinical development. In addition, Vela Laboratories also has development programs underway that aim at improving the efficacy and tolerability of therapeutic antibodies through targeted changes to the sugar structure of the antibody molecules.

The Company, headquartered in Vienna, Austria, was founded in November 2006. Vela Laboratories is funded by private investors, by grants from Austrian government agencies (AWS and ZIT/LISA) and through revenues generated by its analytical services business.

Contact:

Jakob Koschutnig

Head Marketing & Sales

Vela Laboratories

Brunner Str. 69 / 3

1230 Vienna, Austria

Mobile: +43(0)699-1314-3-123

Fax: +43(0)1-890-597-9-10

E-mail: j.koschutnig@vela-labs.at

Web: http://www.vela-labs.at


'/>"/>
SOURCE Vela Laboratories
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. IDEXX Laboratories Announces First Customer Deliveries of Catalyst Dx(TM) Chemistry Analyzer and SNAPshot Dx(TM) Analyzer
2. Stonegate Report About Unigene Laboratories Inc.
3. Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego
4. White Paper Details Environmental Health & Safety Compliance Strategies for Laboratories
5. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
6. Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation
7. Clontech Laboratories, Inc. Releases the ProteoTuner(TM) Systems
8. Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringement
9. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
10. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
11. Free White Paper Helps Biotech Laboratories Maintain a High Level of Infection Control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, ... of the Supplyframe Design Lab . Located in Pasadena, Calif., the Design ... of how hardware projects are designed, built and brought to market. , The ...
Breaking Biology Technology:
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
(Date:4/26/2016)... and LONDON , April 26, ... of EdgeVerve Systems, a product subsidiary of Infosys ... announced a partnership to integrate the Onegini mobile ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... customers enhanced security to access and transact across ...
Breaking Biology News(10 mins):